Paul M. Rival

Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions

Androgen deprivation therapy remains the cornerstone of systemic treatment for advanced prostate cancer. However, progression to castration-resistant prostate cancer (CRPC) is almost inevitable. Supraphysiological androgen exposure can suppress tumor growth in selected biological...